Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Few strategies are available for the prevention of cognitive impairment in elderly persons. Serum lipoprotein levels may be important predictors of cognitive function, and drugs that lower cholesterol may be effective for the prevention of cognitive impairment. OBJECTIVE: To determine whether serum lipoprotein levels, the 4-year change in serum lipoprotein levels, and the use of statin drugs are associated with cognition in older women without dementia. DESIGN, SETTING, AND PARTICIPANTS: An observational study of 1037 postmenopausal women with coronary heart disease enrolled in the Heart and Estrogen/progestin Replacement Study (participants at 10 of 20 centers). MAIN OUTCOME MEASURE: The Modified Mini-Mental State Examination was administered at the end of the study after 4 years of follow-up. Women whose score was less than 84 points (>1.5 SDs below the mean) were classified as having cognitive impairment. Lipoprotein levels (total, high-density lipoprotein, and low-density lipoprotein [LDL] cholesterol and triglycerides) were measured at baseline and at the end of the study; statin use was documented at each visit. RESULTS: Compared with women in the lower quartiles, women in the highest LDL cholesterol quartile at cognitive testing had worse mean plus minus SD Modified Mini-Mental State Examination scores (93.7 plus minus 6.0 vs 91.9 plus minus 7.6; P =.002) and an increased likelihood of cognitive impairment (adjusted odds ratio, 1.76; 95% confidence interval, 1.04-2.97). A reduction in the LDL cholesterol level during the 4 years tended to be associated with a lower odds of impairment (adjusted odds ratio, 0.61; 95% confidence interval, 0.36-1.03) compared with women whose levels increased. Higher total and LDL cholesterol levels, corrected for lipoprotein(a) levels, were also associated with a worse Modified Mini-Mental State Examination score and a higher likelihood of impairment, whereas high-density lipoprotein cholesterol and triglyceride levels were not associated with cognition. Compared with nonusers, statin users had higher mean plus minus SD Modified Mini-Mental State Examination scores (92.7 plus minus 7.1 vs 93.7 plus minus 6.1; P =.02) and a trend for a lower likelihood of cognitive impairment (odds ratio, 0.67; 95% confidence interval, 0.42-1.05), findings that seemed to be independent of lipid levels. CONCLUSIONS: High LDL and total cholesterol levels are associated with cognitive impairment, and lowering these lipoprotein levels may be a strategy for preventing impairment. The association between statin use and better cognitive function in women without dementia requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
(1987) · PubMed · Cited by 2,657
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,166
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758
Cited by
Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
Self-citationBrain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044
The metabolic syndrome, inflammation, and risk of cognitive decline
Yaffe, K. (2004) · JAMA · doi:10.1001/jama.292.18.2237 · Cited by 1,025
“Stroke history 17 (1) 16 (2) 10 (3) 12 (4) .”
BackgroundInfluentialSelf-citationKinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Statin-Associated Side Effects
Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 739
Alzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
Castellani, R. J., Rolston, R. K., & Smith, M. A. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.001 · Cited by 519
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Cognitive Impairment in Chronic Kidney Disease
Kurella, M., Chertow, G. M., Luan, J., & Yaffe, K. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52508.x · Cited by 472
Self-citationKurella, M., Chertow, G. M., Fried, L. F., Cummings, S. R., Harris, T., Simonsick, E., Satterfield, S., Ayonayon, H., & Yaffe, K. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010005 · Cited by 458
Self-citationPharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Mixed Dementia: Emerging Concepts and Therapeutic Implications
Langa, K. M., Foster, N. L., & Larson, E. B. (2004) · JAMA · doi:10.1001/jama.292.23.2901 · Cited by 398
Predictors of maintaining cognitive function in older adults: The Health ABC Study
Yaffe, K., Fiocco, A. J., Lindquist, K., Vittinghoff, E., Simonsick, E. M., Newman, A. B., Satterfield, S., Rosano, C., Rubin, S. M., Ayonayon, H. N., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a92c36 · Cited by 396
Self-citationSuzuki, T., Shimada, H., Makizako, H., Doi, T., Yoshida, D., Ito, K., Shimokata, H., Washimi, Y., Endo, H., & Kato, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061483 · Cited by 384
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Wolozin, B., Wang, S. W., Li, N.-C., Lee, A., Lee, T. A., & Kazis, L. E. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-20 · Cited by 383
Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature
Wagstaff, L. R., Mitton, M. W., Arvik, B. M., & Doraiswamy, P. M. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.871.32720 · Cited by 366
Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Cholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
Cholesterol in Alzheimer's disease
Shobab, L. A., Hsiung, G.-Y. R., & Feldman, H. H. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70248-9 · Cited by 336
Oblak, A. L., Lin, P. B., Kotredes, K. P., Pandey, R. S., Garceau, D., Williams, H. M., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.713726 · Cited by 325
“Similarly, (E)-4-(2-(6-(2-(2-(2-([18F]Fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine ([18F]-AV45) was synthesized, purified, and prepared according to established methods (Yao et al., 2010).”
MethodCardiovascular disease and Alzheimer's disease: common links
STAMPFER, M. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01687.x · Cited by 324
The NIH Cognitive and Emotional Health Project: Report of the Critical Evaluation Study Committee
Hendrie, H. C., Albert, M. S., Butters, M. A., Gao, S., Knopman, D. S., Launer, L. J., Yaffe, K., Cuthbert, B. N., Edwards, E., & Wagster, M. V. (2006) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.11.004 · Cited by 323
Self-citationYaffe, K., Ackerson, L., Tamura, M. K., Le Blanc, P., Kusek, J. W., Sehgal, A. R., Cohen, D., Anderson, C., Appel, L., DeSalvo, K., et al. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02670.x · Cited by 313
Self-citationZandi, P. P. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.217 · Cited by 310
Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer’s Disease
Roher, A. E., Esh, C., Kokjohn, T. A., Kalback, W., Luehrs, D. C., Seward, J. D., Sue, L. I., & Beach, T. G. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000095973.42032.44 · Cited by 280
Walhovd, K. B., Fjell, A. M., Brewer, J., McEvoy, L. K., Fennema-Notestine, C., Hagler, D. J., Jennings, R. G., Karow, D., Dale, A. M., & Initiative, T. A. D. N. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1809 · Cited by 279
Cerebrovascular Reactivity and Cognitive Decline in Patients With Alzheimer Disease
Silvestrini, M., Pasqualetti, P., Baruffaldi, R., Bartolini, M., Handouk, Y., Matteis, M., Moffa, F., Provinciali, L., & Vernieri, F. (2006) · Stroke · doi:10.1161/01.str.0000206439.62025.97 · Cited by 278
Farias, S. T., Mungas, D., & Jagust, W. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1367 · Cited by 276
Statins: Mechanisms of neuroprotection
van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.002 · Cited by 268
“Several studies did not find any effect on cognitive functioning (Collins et al., 2004; Santanello et al., 1997; Shepherd et al., 2002) whereas others found a significant improvement (Cramer et al., 2008; Hajjar et al., 2002; Rodriguez et al., 2002; Yaffe et al., 2002).”
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
“Four cohort studies (n 7368) (27, 30, 34, 40) showed no difference between statin and placebo groups in end-of-study or change in global cognitive performance evaluated through varied composite scores (Table 10 of Supplement 2).”
BackgroundSierra, S., Ramos, M. C., Molina, P., Esteo, C., Vázquez, J. A., & Burgos, J. S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101179 · Cited by 248
Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study
Li, G., Higdon, R., Kukull, W. A., Peskind, E., Van Valen Moore, K., Tsuang, D., van Belle, G., McCormick, W., Bowen, J. D., Teri, L., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000142963.90204.58 · Cited by 246
Statin Adherence and Risk of Accidents: A Cautionary Tale
Dormuth, C. R., Patrick, A. R., Shrank, W. H., Wright, J. M., Glynn, R. J., Sutherland, J., & Brookhart, M. A. (2009) · Circulation · doi:10.1161/circulationaha.108.824151 · Cited by 244
Brain imaging evidence of preclinical Alzheimer's disease in normal aging
Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D., & Haan, M. (2006) · Annals of Neurology · doi:10.1002/ana.20799 · Cited by 222
The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women
Yaffe, K., Weston, A. L., Blackwell, T., & Krueger, K. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.566 · Cited by 220
Self-citationEnzyme-Amplified Array Sensing of Proteins in Solution and in Biofluids
Miranda, O. R., Chen, H.-T., You, C.-C., Mortenson, D. E., Yang, X.-C., Bunz, U. H. F., & Rotello, V. M. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1006756 · Cited by 213
Preoperative Use of Statins Is Associated with Reduced Early Delirium Rates after Cardiac Surgery
Katznelson, R., Djaiani, G. N., Borger, M. A., Friedman, Z., Abbey, S. E., Fedorko, L., Karski, J., Mitsakakis, N., Carroll, J., & Beattie, W. S. (2009) · Anesthesiology · doi:10.1097/aln.0b013e318190b4d9 · Cited by 209
“of elderly women taking statins.(43) Statins also reduced the risk of dementia in the elderly,(44,45) and its use was associated with decreased incidence of postoperative stroke after cardiac surgery.”
BackgroundReitz, C., Tang, M.-X., Schupf, N., Manly, J. J., Mayeux, R., & Luchsinger, J. A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.297 · Cited by 205
Dregan, A., Stewart, R., & Gulliford, M. C. (2013) · Age and Ageing · doi:10.1093/ageing/afs166 · Cited by 195
Association between Statin Use and Alzheimer’s Disease
Zamrini, E., McGwin, G., & Roseman, J. M. (2004) · Neuroepidemiology · doi:10.1159/000073981 · Cited by 202
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology
Arvanitakis, Z., Schneider, J. A., Wilson, R. S., Bienias, J. L., Kelly, J. F., Evans, D. A., & Bennett, D. A. (2008) · Neurology · doi:10.1212/01.wnl.0000288181.00826.63 · Cited by 199
Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
The metabolic syndrome is associated with decelerated cognitive decline in the oldest old
van den Berg, E., Biessels, G. J., de Craen, A. J. M., Gussekloo, J., & Westendorp, R. G. J. (2007) · Neurology · doi:10.1212/01.wnl.0000271381.30143.75 · Cited by 193
Metabolic Syndrome and Cognitive Disorders: Is the Sum Greater Than Its Parts?
Yaffe, K. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318065bfd6 · Cited by 185
Self-citationCurrent approaches in the treatment of Alzheimer's disease
Shah, R. S., Lee, H.-G., Xiongwei, Z., Perry, G., Smith, M. A., & Castellani, R. J. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.005 · Cited by 172
Neuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
Serum Cholesterol and Cognitive Performance in the Framingham Heart Study
Elias, P. K., Elias, M. F., D’Agostino, R. B., Sullivan, L. M., & Wolf, P. A. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000151745.67285.c2 · Cited by 168
Brain cholesterol in normal and pathological aging
Martin, M., Dotti, C. G., & Ledesma, M. D. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.011 · Cited by 162
The involvement of lipid rafts in Alzheimer's disease (Review)
Cordy, J. M., Cordy, J. M., Hooper, N. M., & Turner, A. J. (2006) · Molecular Membrane Biology · doi:10.1080/09687860500496417 · Cited by 157
Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020018 · Cited by 154
“Reports from retrospective analyses suggest that the statin class of cholesterol-lowering HMGCoA reductase inhibitors may lower the risk for Alzheimer disease by as much as 70% [8,9,10,11].”
BackgroundAlzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Serum total cholesterol, statins and cognition in non-demented elderly
Solomon, A., Kåreholt, I., Ngandu, T., Wolozin, B., MacDonald, S. W. S., Winblad, B., Nissinen, A., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.09.012 · Cited by 149
Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases
Wang, Q., Yan, J., Chen, X., Li, J., Yang, Y., Weng, J., Deng, C., & Yenari, M. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2010.04.006 · Cited by 130
Acharya, N. K., Levin, E. C., Clifford, P. M., Han, M., Tourtellotte, R., Chamberlain, D., Pollaro, M., Coretti, N. J., Kosciuk, M. C., Nagele, E. P., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122254 · Cited by 121
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Burgess, B. L., McIsaac, S. A., Naus, K. E., Chan, J. Y., Tansley, G. H. K., Yang, J., Miao, F., Ross, C. J. D., van Eck, M., & Hayden, M. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.007 · Cited by 115
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
Morley, J. E., & Banks, W. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091576 · Cited by 108
“A variety of population based studies have suggested that statin therapy is associated with a decrease in dementia [30–36].”
Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E
Fan, J., Donkin, J., & Wellington, C. (2009) · BioFactors · doi:10.1002/biof.37 · Cited by 97
Targets for the Prevention of Dementia
Middleton, L. E., & Yaffe, K. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091657 · Cited by 94
“People with high levels of low-density lipoproteins in late life have in-L creased risk of cognitive impairmentand dementia with stroke [82,83].”
Self-citationCholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease
Rudajev, V., & Novotny, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937056 · Cited by 94
Cholesterol and statins in Alzheimer’s disease: current controversies.
Fonseca, A. C. R. G., Resende, R., Oliveira, C. R., & Pereira, C. M. F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.013 · Cited by 93
Albanese, E., Dangour, A. D., Uauy, R., Acosta, D., Guerra, M., Guerra, S. S. G., Huang, Y., Jacob, K., Llibre de Rodriguez, J., Noriega, L. H., et al. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27580 · Cited by 89
Fong, L. K., Yang, M. M., dos Santos Chaves, R., Reyna, S. M., Langness, V. F., Woodruff, G., Roberts, E. A., Young, J. E., & Goldstein, L. S. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000441 · Cited by 72
The Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
Midlife lipid and glucose levels are associated with Alzheimer's disease
Zhang, X., Tong, T., Chang, A., Ang, T. F. A., Tao, Q., Auerbach, S., Devine, S., Qiu, W. Q., Mez, J., Massaro, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12641 · Cited by 65
ACAT inhibition and amyloid beta reduction
Bhattacharyya, R., & Kovacs, D. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.04.003 · Cited by 53
Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
Ma, C., Li, J., Bao, Z., Ruan, Q., & Yu, Z. (2015) · BioMed Research International · doi:10.1155/2015/481621 · Cited by 46
“The subjects for the study were divided into three groups according to MMSE scores: group 1 (28 ≤ MMSE≤ 30), group 2 (24≤MMSE≤ 27), and group 3 (MMSE ≤ 23).”
BackgroundCholesterol and Alzheimer's disease
Wolozin, B. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300525 · Cited by 33
ApoE4: is it the absence of good or the presence of bad?
Ashford, J. W. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4303 · Cited by 21
Fiocco, A. J., Krieger, L., D’Amico, D., Parrott, M. D., Laurin, D., Gaudreau, P., Greenwood, C., & Ferland, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.04.008 · Cited by 21
Nandeesha, H., Keshri, N., Rajappa, M., & Menon, V. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1839500 · Cited by 17
“Previous studies have documented that elevated total cholesterol and low-density lipoprotein (LDL) cholesterol increase the risk of cognitive dysfunction in elderly Chinese population and suggested use of statins for improvement of cognitive functions (Yaffe et al. 2002, Ma et al. 2017).”
BackgroundZhang, G., Ye, X., Wang, X., Lin, Y., Zhu, C., Pan, J., Yin, X., Ye, M., Lv, W., Tang, W., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.03.046 · Cited by 9
Real-life helping behaviours in North America: A genome-wide association approach.
Primes, G., & Fieder, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190950 · Cited by 4
Gene Transfer Induced Hypercholesterolemia in Amyloid Mice
Grames, M. S., Dayton, R. D., Lu, X., Schilke, R. M., Alexander, J. S., Orr, A. W., Barmada, S. J., Woolard, M. D., & Klein, R. L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180494 · Cited by 4
Simeone, P. G., Vadini, F., Tripaldi, R., Liani, R., Ciotti, S., Di Castelnuovo, A., Cipollone, F., & Santilli, F. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.632655 · Cited by 3
“, 2009) and high LDL and total cholesterol levels have been associated with cognitive impairment in old women (Yaffe et al., 2002), the observation of no correlation between short-term memory and cholesterol levels in our group of patients (data not shown) prevented us to support the hypothesis of an effect mediated b…”
Background
Metadata
- Authors
- Yaffe, K., Barrett-Connor, E., Lin, F., & Grady, D.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2002-03-01
- Volume
- 59
- Issue
- 3
- Pages
- 378
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2123457140
- Cited by
- 439
- References
- 30
- FWCI
- 26.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.